Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Tetrazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 9/20 | 0.62 |
| ▸ | GABRA5 known ✓ | P31644 | 9/20 | 0.62 |
| ▸ | GABRA2 known ✓ | P47869 | 9/20 | 0.62 |
| ▸ | GABRG2 known ✓ | P18507 | 8/20 | 0.62 |
| ▸ | GABRB3 known ✓ | P28472 | 8/20 | 0.62 |
| ▸ | GABRA3 known ✓ | P34903 | 8/20 | 0.62 |
| ▸ | GABRB2 known ✓ | P47870 | 6/20 | 0.62 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.62 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.62 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.62 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.62 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.62 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.62 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.62 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.62 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | TSPO | P30536 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrazepam SCHEMBL29500955 | 1.00 | LMNA (0.65) | LMNAGAATSPOGABRA1GABRA5 | |
| Tetrazepam SCHEMBL6832326 | 0.99 | LMNA (0.63) | LMNAGAATSPOGABRA1GABRA5 | |
| Fludiazepam SCHEMBL6130061 | 0.90 | GABRA1 (0.57) | LMNAGAATSPOGABRA1GABRA5 | |
| SCHEMBL13352296 | 0.87 | LMNA (0.47) | LMNAGAATSPOGABRA1GABRA5 | |
| Tetrazepam SCHEMBL20586241 | 0.83 | GABRA1 (0.49) | LMNAGAATSPOGABRA1GABRA5 | |
| SCHEMBL5163739 | 0.83 | GABRA1 (0.61) | LMNAGAATSPOGABRA1GABRA5 | |
| Menitrazepam SCHEMBL1005402 | 0.82 | LMNA (0.65) | LMNAGAATSPOGABRA1GABRA5 | |
| Cyclobenzaprine SCHEMBL28142913 | 0.81 | GABRA1 (0.47) | LMNAGAATSPOGABRA1GABRA5 | |
| Tetrazepam SCHEMBL28086699 | 0.81 | GABRA1 (0.47) | LMNAGAATSPOGABRA1GABRA5 | |
| SCHEMBL14316091 | 0.81 | LMNA (0.63) | LMNAGAATSPOGABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2240 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375421-A1 | METHODS OF USING DMT | SHULMAN WILLIAM (US) | 2025-12-11 | — | — | US | claimed |
| US-12396981-B2 | Methods of using DMT | SHULMAN WILLIAM (US) | 2025-08-26 | — | — | US | claimed |
| US-20240401041-A1 | METHODS FOR IMPROVING RELAXATION OF STRIATED MYOCYTES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-12-05 | — | — | US | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20240299355-A1 | METHODS OF USING DMT | SHULMAN WILLIAM (US) | 2024-09-12 | — | — | US | claimed |
| EP-4367243-A1 | METHODS FOR IMPROVING RELAXATION OF STRIATED MYOCYTES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2024-05-15 | — | — | EP | claimed |
| EP-3192499-B1 | CELLULOSE FIBRE BASED SUPPORT MATRICES FOR LAYERED PRODUCTS FOR ORAL AND PERORAL APPLICATION AND THEIR PREPARATION | GLATT GMBH (DE) | 2023-11-29 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| WO-2023280988-A1 | METHODS FOR IMPROVING RELAXATION OF STRIATED MYOCYTES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-01-12 | — | — | WO | claimed |
| US-20220362160-A1 | ABUSE RESISTANT CAPSULE | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-11-17 | — | — | US | claimed |
| CN-1215322-A | Method for encapsulating caplets in capsules and solid dosage forms obtainable by this method | WARNER LAMBERT CO (US) | 1999-04-28 | — | — | CN | claimed |
| EP-0891180-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1999-01-20 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| CN-1170346-A | Process for encapsulation of caplets in capsule and solid dasage forms obtainable by such process | WARNER LAMBERT CO (US) | 1998-01-14 | — | — | CN | claimed |
| WO-1997037629-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1997-10-16 | — | — | WO | claimed |
| EP-0797424-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1997-10-01 | — | — | EP | claimed |
| WO-1996018370-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1996-06-20 | — | — | WO | claimed |
| US-5248678-A | Administering adenosine receptor antagonist and a GABA antagonist | FRACTAL LABORATORIES, INC. (US) | 1993-09-28 | — | — | US | claimed |
| EP-0050487-A1 | Pharmaceutical compositions comprising a benzodiazepine drug and a phenanthridine derivative | PFIZER INC. (US) | 1982-04-28 | — | — | EP | claimed |
| US-4320124-A | ANALGESICS | PFIZER INC. (US) | 1982-03-16 | — | — | US | claimed |